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Abstract 1 
Clinical scores (i.e. CHA2DS2-VASc) are the mainstay of thromboembolic risk management in 2 
nonvalvular atrial fibrillation (AF). Nonetheless, they bear some limitations to precisely define risk-3 
benefit ratio of oral anticoagulation (OAC), both with vitamin K antagonists (VKA) and with novel 4 
direct oral anticoalants (DOAC), especially in patients with low-intermediate scores. 5 
Cardiovascular imaging, allowing to directly visualize those patho-physiological alterations which 6 
may lead to the formation of intracardiac thrombi, offers itself as a unique tool helping to refine 7 
thromboembolic risk stratification. Many parameters have been tested, focusing primarily on 8 
functional and morphological variables of the left atrium (LA) and left atrial appendage (LAA). LA 9 
volume and LAA peak flow velocity have, since long-time, been associated with increased 10 
thromboembolic risk, while some new parameters, as LA fibrosis assessed by late-gadolinium 11 
enhanced (LGE) magnetic resonance imaging (MRI), LA and LAA strain and LAA morphology 12 
have more recently shown some ability in predicting embolic events in AF patients. Overall, 13 
however, these parameters have seen, to date, a scarce clinical implementation, especially due to 14 
inconsistency of validated cut-offs and/or strong clinical evidences driven by technical limitations, 15 
such as expensiveness of the technologies (i.e. MRI or computed tomography), invasiveness (i.e. 16 
transesophageal echocardiography) or limited reproducibility (i.e. LGE MRI). In conclusion, to 17 
date, cardiovascular imaging plays a limited role, however, validation and diffusion of the new 18 
techniques hereby systematically presented hold the potential to refine thromboembolic risk 19 
stratification in nonvalvular AF.  20 
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GLOSSARY 1 
 2 
3D three-dimensional 
AF atrial fibrillation 
 AP antero-posterior 
AUC area under the curve 
CT computed tomography 
DOAC direct oral anticoagulant 
LA left atrium 
LAA left atrial appendage 
LAAmax area maximal area of LAA 
LAAv LAA peak flow velocities 
LAVI left atrial volume index 
LGE late gadolinium enhancement 
LVEF left ventricular ejection fraction 
MRI magnetic resonance imaging 
OAC oral anticoagulation 
SEC spontaneous echo-contrast 
SR sinus rhythm 
TDI tissue-Doppler imaging 
TEE trans-esophageal echocardiography 
TIA transient ischemic attack 
TTE trans-thoracic echocardiography 
VKA vitamin K antagonist 
 3 
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Introduction 1 
Atrial fibrillation (AF) is a known risk factor for thromboembolic events, especially stroke and 2 
transient ischemic attack (TIA)1. Indeed, recent data suggest that eliminating the arrhythmia may 3 
achieve superior results, compared to simple rate control, in terms of survival2, stroke incidence3 4 
and decline in cognitive functions4. However, when rhythm control strategy is not indicated or fails, 5 
oral anticoagulation (OAC), both with vitamin K antagonists (VKA) or novel direct oral 6 
anticoalants (DOAC), is  , the only treatment to prevent thromboembolic events. For these reasons 7 
on a daily basis, physicians are required to perform an accurate assessment of the risk-benefit ratio 8 
for VKAs or each different DOACs5 in patients with AF, balancing the implicit bleeding risk. 9 
Several clinical scores, such as the CHA2DS2-VASc score, have been proposed and more less 10 
reliably identify patients potentially benefiting from OAC6, considering clinical variables that most 11 
strongly predict not only strokes/TIAs but also AF recurrences following transcatheter ablation7 and 12 
electrical or pharmacological cardioversions8.  Even if usually reliable, CHA2DS2-VASc score still 13 
remains inadequate in several clinical circumstances, particularly in patients at low/intermediate 14 
risk (i.e., CHA2DS2-VASc 1), for whom net clinical benefit of VKAs and even of DOACs is 15 
seriously counterbalanced by the bleeding risk9,10,11,12. Trying to overcome this gap in evidence and 16 
recommendations, a number of alternative parameters have been investigated, evaluating their value 17 
to guide clinical decision-making. Special focus, in fact, has been directed towards the left atrium 18 
(LA) and left atrial appendage (LAA), as they harbour the vast majority of thrombi forming during 19 
nonvalvular AF13,14.  20 
Aim of the present article is to methodologically review these alternative parameters and their 21 
application to nonvalvular AF, discussing if and which may aid the physician in everyday activity.  22 
 23 
 24 
 25 
5  
Spontaneous echocontrast and thrombi 1 
Any discussion concerning LA and LAA and the risk of thromboembolic events in patients with AF 2 
has to deal first with the two strongest predictors of cardioembolic stroke, the presence of thrombi 3 
or spontaneous echo-contrast (SEC) in the LA or LAA15. The relationship between these findings 4 
and the risk of subsequent cardioembolic stroke is known since the dawning of echocardiography. 5 
Presence of thrombi represents the ultimate stage before the clinical event, even if their presence 6 
doesn’t necessarily end in peripheral embolization16,17. SEC represents instead the most obvious 7 
visual representation of the blood stasis occurring during atrial dysrhythmias. Its presence is graded, 8 
depending from intensity, on a scale ranging from 0 to 4 (0, absence of SEC; 4, severe SEC with 9 
intense echodensity and very slow swirling patterns in the LAA and usually LA; 1, 2 and 3 mild, 10 
mild to moderate and moderate SEC, respectively, with intermediate features compared to 0 and 11 
4)18, and its relationship with subsequent embolic events has been consistently demonstrated19,20.  12 
Prevalence of thrombi is highly variable depending on clinical setting: in consecutive, 13 
anticoagulated patients undergoing AF ablation, they have been reported in 0.6%-3.6% of the 14 
patients21,22, while higher figures have been described in different clinical settings (up to 5.9%-15 
16.5%23,24,25). Prevalence of SEC, also varies widely:  for example it ranged from 35% in the large 16 
cohort of anticoagulated patients undergoing AF ablation enrolled by Puwanant et al. (80% of 17 
patients with CHADS2 score 0-1, 13% valvular AF, 9% with left ventricular ejection fraction 18 
[LVEF] < 35%)21, to 8% in the study by Kleemann and colleagues (nonvalvular AF, CHADS2 score 19 
0-1). 20 
Despite their strong and consistent ability to predict stroke and other cardioembolic events, these 21 
parameters, however, present, at least, two main limitations: first, they represent an advanced grade 22 
of prothrombotic state, the last step before a clinical event, so that they’re rarely useful for patients 23 
with recent onset of AF or at low/intermediate clinical risk in whom a decision on OAC 24 
6  
prescription has to be made; second, these alterations are recorded by trans-esophageal 1 
echocardiography (TEE) and only rarely by trans-thoracic echocardiography (TTE).  2 
For these reasons, other parameters have been assessed, often referring to thrombi or SEC as 3 
surrogate study end-points.   4 
 5 
Morphological and structural assessment 6 
Left atrium 7 
During AF, LA enlargement is a common finding, as it comes both as a cause and as a consequence 8 
of the arrhythmia26,27. Since echocardiography became available, a correlation between LA 9 
dimensions as measured by antero-posterior (AP) diameter and thromboembolic risk was seeked, 10 
resulting in contradictory data28,29,30,31. In 1995, data from a prospective cohort of 1,371 men and 11 
1,728 women (of whom approximately 1.8% with AF) included in the Framingham study reported a 12 
significant association between LA AP diameter as measured by M-mode echocardiography and the 13 
risk of stroke and death. The relative risk of stroke was 2.4 per 10 mm increment in men (95% CI, 14 
1.6 to 3.7) and 1.4 in women (95% CI, 0.9 to 2.1), and, when controlling for prevalent and interim 15 
AF, it remained significant, even if with a weaker association (2.0 for men, 1.2 for women)32. More 16 
recently a study on 500 consecutive patients, admitted to hospital for stroke or TIA (15.6% with 17 
AF), confirmed LA AP diameter as an independent predictor for SEC/thrombi33 and LA AP 18 
diameter, evaluated by multi-detector computed tomography (CT) in 67 patients admitted to 19 
hospital for stroke was found to be significantly increased as compared to AF controls without 20 
stroke34. On the other side, a meta-analysis performed on individual data from 1,066 patients 21 
enrolled in three large clinical trials from late 80s – early 90s35,36,37 showed that LA AP diameter 22 
did not predict stroke neither at univariate analysis nor when adjusted for clinical predictors38. 23 
Similar results arose from a prospective study assessing the prognostic implications of SEC15 and 24 
by a post-hoc analysis39 of the Atrial Fibrillation Follow-up Investigation of Rhythm Management  25 
7  
(AFFIRM) trial40, a study in which 4,060 patients with recurrent AFwere randomised to rhythm 1 
control strategy vs. rate control strategy.  2 
Given these data inconsistencies it becomes evident that other LA parameters need to be assessed in 3 
relationship to thromboembolic events. LA area related, in AF patients, to TEE high-risk features 4 
for thromboembolic events41 and, when integrated with LV dysfunction, evidently enhanced the 5 
performance of CHADS2 and CHA2DS2-VASc clinical scores to recognize patients at high 6 
thromboembolic risk42. However, also for LA area data are contradictory, as, for example, in the 7 
1994 study by Fatkin and colleagues, no significant relationship arose between LA area and SEC or 8 
LA thrombi18. 9 
LA volume assessed by transthoracic echocardiography has been more widely tested, and, 10 
especially when indexed for body surfaced (left atrial volume index, LAVI), it showed more 11 
consistent interaction with clinical events. LA volume, both total and indexed for body surface, 12 
significantly related to LAA thrombi at TEE examination41,43,44. In two distinct studies from 13 
populations based in Olmsted County, increased LAVI (≥ 32 ml/mq) related to cardiovascular 14 
adverse events: in the first report, enrolling 1,160 elderly patients (75.5 years) in sinus rhythm (SR), 15 
the predictive value of LAVI was validated in a multivariate model45, while in the second study, 16 
which involved 46 young adults (< 60 years) with lone AF followed for a median of 27 years, the 17 
association was confirmed only in a univariate setting, due to the low number of index events46. 18 
Although suggestive LA enlargement is strictly dependent on its underlying cause. Indeed, Ayirala 19 
and colleagues reported that the predictive value of LAVI for LAA thrombi at TEE was stronger 20 
when LA enlargement was associated with a reduction in LVEF47, while, in an Olmsted County-21 
based cohort of 2,042 patients with more than 45 years (3% with a history of AF), Pritchett et al. 22 
found that the relationship between LAVI and mortality did not persist when controlling for 23 
diastolic dysfunction48, a possible predictor per se of embolic events in AF49. Despite the 24 
8  
aforementioned data, however, to date, no conclusive evidence supports the use of LA enlargement 1 
markers to predict embolic events in AF.  2 
Eventually, progresses in magnetic resonance imaging (MRI), particularly with the development of 3 
late-gadolinium enhancement (LGE) imaging, have been employed to assess structural changes of 4 
atrial myocardium. Particularly, a dedicated protocol, first developed by a research group based in 5 
Salt Lake City, allowed to semi-quantify LA fibrosis and to classify it in four classes based on its 6 
extension (Utah classes I-IV)50. LA LGE extent assessed by this method related to AF recurrence 7 
after ablation51 and, more interestingly, to the presence of thrombi detected by TEE52 and with a 8 
medical history of previous stroke53 (figure 1). Despite its brilliant promises, this technique has 9 
embraced to date little diffusion, probably due to the high costs of MRI and the absence of 10 
prospective validation54. This type of analysis is moreover penalised by the development of 11 
different algorithms in different centres, a substantial limit to the standardisation of the results. For 12 
this reason, a public challenge was launched trying to determine the better performing algorithm 13 
and, even if no definite results were reached, this attempt may be a foundation stone in the diffusion 14 
and widespread adoption of this evaluation55. 15 
 16 
Left atrial appendage  17 
Concerning LAA dimensions, interpretation of existing literature is, unfortunately, even more 18 
inconclusive. A paucity of data has been published and, since LAA measurements are far less 19 
standardized than LA, generalizations of results and comparisons are indeed challenging.  20 
Usually, LAA abnormalities are related to LA alterations56,57,58, even if some peculiar traits can be 21 
found, making a dedicated analysis of LAA worth a chance. Indeed, LAA enlargement doesn’t 22 
always coincide with increased LA size (and viceversa)59, and, at least in patients in SR, LAA peak 23 
9  
flow velocity doesn’t relate to any echocardiographic parameter connected with LA except than A’ 1 
measured at tissue-Doppler imaging (TDI)60.  2 
Pollick and colleagues reported that a bigger maximal LAA (LAAmax) area (and not LA AP 3 
diameter) as measured by TEE related to the presence of thrombi and/or SEC in 19 non-4 
anticoagulated patients with valvular and nonvalvular AF59, and, while another study confirmed this 5 
finding61, other laboratories failed to consistently relate LAA area to an increased risk of stroke62 or 6 
thromboembolic events63,64.  7 
LAA size analysis by CT or MRI also generally did not provide strong evidences in favour of a role 8 
of LAA volume. Two studies reported a direct correlation between increased LAA volumes and 9 
previous stroke, even after controlling for possible confounding factors, with an ideal cut-off for 10 
significant risk increase at 34 ml3 65, but the majority of experiences did not confirm this 11 
relationship66,67,68,69. 12 
More recently, LAA morphology, by CT or MRI, has been proposed to be described in four 13 
different morphologies (Cactus, Chicken Wing, Windsock and Cauliflower) based on the 14 
characteristics of the main and secondary lobes70. By this categorization LAA morphology related 15 
to thromboembolic events: it was first demonstrated that, in patients undergoing AF transcatheter 16 
ablation, Chicken Wing, the most frequent LAA morphology, independently related to the absence 17 
of previous stroke/TIA69, and that the prevalence of silent cerebral ischemic lesions increased with 18 
growing complexity of LAA morphology, from Cactus, the more simple, through Chicken Wing, 19 
Windsock and Cauliflower, the more complex71(figure 2). Once again, further studies brought 20 
controversial results: two experiences, indeed, confirmed the existence of a relationship between 21 
LAA morphology and cerebrovascular events, even if with some slight differences (Kimura and 22 
colleagues identified Cauliflower as the high-risk morphology72, Kosiuk et al. Chicken Wing73), 23 
while other studies failed to report any correlation between LAA morphology and previous stroke74 24 
10  
and incident stroke or TIA after AF ablation67. Concerning LAA morphology the main limitations 1 
seems to relate to the reproducibility of the classification by CT or MRI74. More interestingly, 2 
however, a recent study by Petersen and colleagues, assessed LAA morphology by three-3 
dimensional (3D) TEE, which resulted non-inferior to CT and MRI [data in press], and found a 4 
correlation, corroborated by multivariate linear regression analysis, between non-Chicken Wing 5 
LAA morphologies and reduced LAA flow velocities75. These latter studies are particularly 6 
promising, as validation of LAA morphology description by echocardiographic techniques may 7 
enhance the routine clinical implementation of this analysis, helping to refine thromboembolic risk 8 
stratification.  9 
 10 
Functional assessment  11 
Left atrium 12 
LA and LAA function impairment that lead to blood stasis are, indeed, at the base of thrombus 13 
formation76. 14 
As for LA size, an impaired LA function has been associated with an unfavourable outcome in non-15 
AF patients: a reduced LA function index (a multiparametric index incorporating LA size, LA 16 
emptying fraction and LV outflow velocity-time integral) significantly related to incident stroke or 17 
TIA at follow up in 893 patients without a known history of AF not on OAC77, while a reduced LA 18 
longitudinal strain, as assessed by speckle tracking, was able to predict development of adverse 19 
events including, among others, AF, stroke or TIA and cardiovascular death in 312 patients in SR78.  20 
More in details, within AF patients, CHADS2 and CHA2DS2-VASc scores significantly related to 21 
an increased LAVI and a reduced LA emptying fraction (LAEF) in a sub-analysis of the ENGAGE 22 
AF-TIMI 48 study. LAVI and LAEF also inversely related to each other, even if only LAVI was 23 
confirmed as an independent predictor after adjusting for confounding factors79. An association 24 
between LA function and CHADS2 and CHA2DS2-VASc scores was also confirmed when LAEF 25 
11  
was assessed by 3D echocardiography80. 1 
In addition, since its introduction and widespread diffusion, strain analysis by speckle tracking has 2 
been increasingly applied also in this field, reporting very promising results. Even if a prospective 3 
validation has yet to been provided, a reduced global longitudinal strain proved to relate to the 4 
extent of fibrosis at MRI81 and not only to an increased CHADS2 or CHA2DS2-VASc score80,82,83, 5 
but to an improved CHADS2 and CHA2DS2-VAScscores ability to identify patients with recent 6 
acute embolic events and to predict mortality at follow up83,84. Interestingly, peak negative and 7 
positive atrial strain were able to discriminate patients with previous stroke or TIA in an AF-cohort 8 
with low intermediate CHADS2 score (≤ 1, of whom 30% with CHA2DS2-VASc≤ 1)85.  9 
 10 
Left atrial appendage  11 
LAA function has been thoroughly investigated since a correlation between reduced LAA peak 12 
flow velocities (LAAv) and increased thromboembolic risk was demonstrated. LAAv tend to reduce 13 
during the course of AF and more decreased values strongly related to the presence of SEC18, and 14 
of LAA thrombi33 and predicted cardioembolic events in a sub-analysis of the SPAF-III study86. 15 
Despite overall consistent results, this parameter has embraced a very limited clinical 16 
implementation, partly due to the variable and widely ranging cut-offs reported (in the 3 17 
aforementioned studies, LAAv relating to adverse events were < 35 cm/s, < 55 cm/s and < 20 cm/s, 18 
respectively 18,33,86), and, partly, because LAAv measurement require TEE.  19 
To overcome this latter limitation, surrogate markers of reduced LAAv have been investigated. As 20 
TEE studies reported a correlation between reduced LAA wall acceleration as measured by TDI and 21 
increased thromboembolic risk87,88, an evaluation of those TDI parameters by TTE has been 22 
attempted, with garbed success. With a good feasibility (> 90%), LAA wall velocity, evaluated 23 
mainly by LAA tip acceleration on a short-axis view, significantly related to reduced LAAv, 24 
presence of SEC or thrombi and previous stroke89,90,91(figure 3). Moreover, these results were 25 
prospectively validate in a cohort of 179 patients with previous thromboembolic stroke related to 26 
12  
AF, in whom an LAA wall velocity < 8.7 cm/s independently predicted recurrent stroke or 1 
cerebrovascular death92. TDI was also used to assess septal and lateral mitral annular a’ wave 2 
velocities, which strongly related to reduced LAAv and SEC60,93. 3 
Eventually a similar proceeding than with TDI was attempted with LAA strain, even if data are, to 4 
date, scarce. In fact, LAA strain predicted the presence of LAA thrombi25, and feasibility of the 5 
evaluation by TTE was confirmed in a series of 82 patients, in whom negative peak strain rate and 6 
time-to-peak positive strain independently related to the presence of LAA thrombi or sludge with an 7 
AUC of 0.8994.   8 
Finally, LAA emptying determined by velocity encoded-MRI had a good correlation with LAAv as 9 
measured by Pulsed Doppler at TEE, opening the doors of LAA functional evaluation to a new 10 
technique95. 11 
 12 
 13 
 14 
Conclusion  15 
LAVI and functional parameters of both LA and LAA consistently predicted stroke in patients with 16 
AF, while promising results came from the application of more recent techniques such as strain and 17 
LAA morphology assessment.  18 
Clinical application of these parameters, however, is to date limited, mostly due to lack of large-19 
scale prospective validation and consequent inability to suggest significant cut-offs.  20 
In our opinion, to date, parameters, such as severely reduced LAAv or markedly enlarged LA, may 21 
aid, in a case-by-case approach, as complementary tools to guide OAC prescription in controversial 22 
and ambiguous cases. In addition, LAA and LA imaging, particularly with the development of 23 
technologies such as TDI or speckle tracking, bears a promising potential. 24 
 25 
13  
 1 
Conflicts of interest: no conflicts of interest pertaining the present work have been reported.  2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
14  
References 1 
                                                        
1 Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial 
fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10):973-7 
2 Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm 
control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch 
Intern Med 2012;172(13):997-1004 
3 Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm versus rate control therapy and subsequent 
stroke or transient ischemic attack in patients with atrial fibrillation. Circulation 
2012;126(23):2680-7 
4 Gaita F, Corsinovi L, Anselmino M, et al. Prevalence of silent cerebral ischemia in paroxysmal 
and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol 
2013;62(21):1990-7 
5 Prisco D, Cenci C, Silvestri E, Ciucciarelli L, Di Minno G. Novel oral anticoagulants in atrial 
fibrillation: which novel oral anticoagulant for which patient? J Cardiovasc Med (Hagerstown). 
2015 Mar 19. [Epub ahead of print] 
6Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for 
predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based 
approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72  
7 Jacobs V, May HT, Bair TL, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) 
on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12(4):681-6 
8 Falsetti L, Viticchi G, Tarquinio N, Silvestrini M, Capeci W, Balloni A, Catozzo V, Gentile A, 
Pellegrini F. CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or 
pharmacological cardioversion. J Cardiovasc Med (Hagerstown). 2014;15(8):636-41 
9 Chao TF, Liu CJ, Wang KL, et al. Should Atrial Fibrillation Patients With 1 Additional Risk 
Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? J Am Coll 
15  
                                                                                                                                                                                        
Cardiol. 2015;65(7):635-42 
10 Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants 
(dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation 
population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 
2012;107(3):584-9 
11 Friberg L, Skeppholm M, Terént A. Benefit of Anticoagulation Unlikely in Patients With Atrial 
Fibrillation and a CHA2DS2-VASc Score of 1. J Am Coll Cardiol. 2015;65(3):225-32 
12 Calkins H. Data Strengthen to Support Recommending Anticoagulant Therapy for All Atrial 
Fibrillation Patients With a CHA2DS2-VASc Score ≥1. J Am Coll Cardiol. 2015;65(7):643-4 
13 Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients 
with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-9 
14 Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation 
stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 
1990;40(7):1046-50 
15 Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left 
atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 
1994;24(3):755-62 
16 Stöllberger C, Chnupa P, Kronik G, et al. Transesophageal echocardiography to assess embolic 
risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann 
Intern Med. 1998;128(8):630-8 
17 Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic 
attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676-82  
18 Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, 
spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 
1994;23(4):961-9 
16  
                                                                                                                                                                                        
19 Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with 
nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee 
on Echocardiography. Ann Intern Med. 1998;128(8):639-47 
20 Lowe BS, Kusunose K, Motoki H, et al. Prognostic significance of left atrial appendage "sludge" 
in patients with atrial fibrillation: a new transesophageal echocardiographic thromboembolic risk 
factor. J Am Soc Echocardiogr. 2014;27(11):1176-83 
21 Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of 
thromboembolic risk in patients with atrial fibrillation undergoing transesophageal 
echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009;54(22):2032-9 
22 Wallace TW, Atwater BD, Daubert JP, et al. Prevalence and clinical characteristics associated 
with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed 
atrial fibrillation ablation. J Cardiovasc Electrophysiol 2010;21(8):849-52 
23 Maltagliati A, Galli CA, Tamborini G, Celeste F, Muratori M, Pepi M. Incidence of spontaneous 
echocontrast, 'sludge' and thrombi before cardioversion in patients with atrial fibrillation: new 
insights into the role of transesophageal echocardiography. J Cardiovasc Med (Hagerstown). 
2009;10(7):523-8 
24 Seidl K, Rameken M, Drögemüller A, et al. Embolic events in patients with atrial fibrillation and 
effective anticoagulation: value of transesophageal echocardiography to guide direct-current 
cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll 
Cardiol. 2002;39(9):1436-42 
25 Ono K, Iwama M, Kawasaki M, et al. Motion of left atrial appendage as a determinant of 
thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent 
nonvalvular atrial fibrillation. Cardiovasc Ultrasound. 2012;10:50.  
17  
                                                                                                                                                                                        
26 Howard C, Dittrich, MD, Lesly A, et al. on behalf of the Stroke Prevention in Atrial Fibrillation 
Investigators. Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Am 
Heart J 1999;137:494-9  
27 Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation  
in older adults. Circulation. 1997;96(7):2455-61 
28 Caplan LR, D'Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation, and stroke. Ann 
Neurol. 1986;19(2):158-61. 
29 Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk factors for 
thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch 
Intern Med. 1990;150(4):819-21 
30 Gustafsson C, Britton M, Brolund F, Eriksson SV, Lindvall K. Echocardiographic findings and 
the increased risk of stroke in nonvalvular atrial fibrillation. Cardiology. 1992;81(4-5):189-95 
31 Corbalán R, Arriagada D, Braun S, et al. Risk factors for systemic embolism in patients with 
paroxysmal atrial fibrillation. Am Heart J. 1992;124(1):149-53 
32 Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of 
stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835-41. 
33 Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A. Left atrial appendage flow 
velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and 
relationship to spontaneous echocontrast and thrombus formation--a transesophageal 
echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 
2005;18(12):1366-72 
34 Lee JM, Shim J, Uhm JS, et al. Impact of increased orifice size and decreased flow velocity of 
left atrial appendage on stroke in nonvalvular atrial fibrillation. Am J Cardiol. 2014;113(6):963-9 
35 Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84(2):527-39. 
18  
                                                                                                                                                                                        
36 Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated 
with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial 
Fibrillation Investigators. N Engl J Med 1992;327(20):1406-12. 
37 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial 
fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J 
Med 1990;323(22):1505-11 
38 Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 
1066 patients from 3 clinical trials. Arch Intern Med. 1998;158(12):1316-20 
39 Olshansky B, Heller EN, Mitchell LB, et al. Are transthoracic echocardiographic parameters 
associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-
Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005;45(12):2026-
33 
40 Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients 
with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33 
41 Faustino A, Providência R, Barra S, et al. Which method of left atrium size quantification is the 
most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation? 
Cardiovasc Ultrasound. 2014;12:28 
42 Providência R, Botelho A, Trigo J, et al. Possible refinement of clinical thromboembolism 
assessment in patients with atrial fibrillation using echocardiographic parameters. Europace 
2012;14(1):36-45 
43 Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial 
thrombi in atrial fibrillation. Am Heart J. 2010;159(4):665-71 
44 Yamamoto M, Seo Y, Kawamatsu N, et al. Complex left atrial appendage morphology and left 
atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging. 
19  
                                                                                                                                                                                        
2014;7(2):337-43 
45 Tsang TS, Barnes ME, Gersh BJ, et al. Prediction of risk for first age-related cardiovascular 
events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol. 
2003;42(7):1199-205 
46 Osranek M, Bursi F, Bailey KR, et al. Left atrial volume predicts cardiovascular events in 
patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J. 
2005;26(23):2556-61 
47 Ayirala S, Kumar S, O'Sullivan DM, Silverman DI. Echocardiographic predictors of left atrial 
appendage thrombus formation. J Am Soc Echocardiogr.2011;24(5):499-505 
48 Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic 
dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005;45(1):87-92 
49 Lee SH, Choi S, Chung WJ, et al. Tissue Doppler index, E/E', and ischemic stroke in patients 
with atrial fibrillation and preserved left ventricular ejection fraction. J Neurol Sci. 2008;271(1-
2):148-52 
50 Akoum N, Daccarett M, McGann C, et al. Atrial fibrosis helps select the appropriate patient and 
strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc 
Electrophysiol. 2011;22(1):16-22. 
51 Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural  
remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial 
fibrillation. Circulation. 2009;119(13):1758-67 
52 Akoum N, Fernandez G, Wilson B, Mcgann C, Kholmovski E, Marrouche N. Association of 
atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast 
on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc 
Electrophysiol. 2013;24(10):1104-9. 
53 Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-
20  
                                                                                                                                                                                        
enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J 
Am Coll Cardiol. 2011;57(7):831-8 
54 Gaita F, Blandino A. Atrial fibrillation. Left atrial fibrosis--a promising stroke risk factor? Nat 
Rev Cardiol. 2011;8(6):307-8.  
55 Karim R, Housden RJ, Balasubramaniam M, et al. Evaluation of current algorithms for 
segmentation of scar tissue from late gadolinium enhancement cardiovascular magnetic resonance 
of the left atrium: an open-access grand challenge. J Cardiovasc Magn Reson. 2013;15:105 
56 Anselmino M, Blandino A, Beninati S, et al. Morphologic analysis of left atrial anatomy by 
magnetic resonance angiography in patients with atrial fibrillation: a large single center experience. 
J Cardiovasc Electrophysiol. 2011;22(1):1-7 
57 Uslu N, Nurkalem Z, Orhan AL, et al. Transthoracic echocardiographic predictors of the left 
atrial appendage contraction velocity in stroke patients with sinus rhythm. Tohoku J Exp Med. 
2006;208(4):291-8 
58 Igarashi Y, Kashimura K, Makiyama Y, Sato T, Ojima K, Aizawa Y. Left atrial appendage 
dysfunction in chronic nonvalvular atrial fibrillation is significantly associated with an elevated 
level of brain natriuretic peptide and a prothrombotic state. Jpn Circ J. 2001;65(9):788-92 
59 Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal 
echocardiography. Implications for the development of thrombus. Circulation. 1991;84(1):223-31 
60 Agmon Y, Khandheria BK, Meissner I, et al. Are left atrial appendage flow velocities adequate 
surrogates of global left atrial function? A population-based transthoracic and transesophageal 
echocardiographic study. J Am Soc Echocardiogr. 2002;15(5):433-40 
61 Ozer N, Kiliç H, Arslan U, et al. Echocardiographic predictors of left atrial appendage 
spontaneous echocontrast in patients with stroke and atrial fibrillation. J Am Soc Echocardiogr. 
2005;18(12):1362-5 
62 Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal 
21  
                                                                                                                                                                                        
echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. 
Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31(7):1622-6 
63 Miyazaki S, Ito T, Suwa M, Nakamura T, Kobashi A, Kitaura Y. Role of transesophageal 
echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial 
fibrillation. Jpn Circ J. 2001;65(10):874-8 
64 Okuyama H, Hirono O, Tamura H, et al. Usefulness of intensity variation in the left atrial 
appendage with contrast echocardiography to predict ischemic stroke recurrence in patients with 
atrial fibrillation. Am J Cardiol. 2008;101(11):1630-7 
65 Burrell LD, Horne BD, Anderson JL, Muhlestein JB, Whisenant BK. Usefulness of left atrial 
appendage volume as a predictor of embolic stroke in patients with atrial fibrillation. Am J Cardiol. 
2013;112(8):1148-52 
66 Kosiuk J, Nedios S, Kornej J, et al. Impact of left atrial appendage morphology on peri-
interventional thromboembolic risk during catheter ablation of atrial fibrillation. Heart Rhythm. 
2014;11(9):1522-7 
67 Nedios S, Kornej J, Koutalas E, et al. Left atrial appendage morphology and thromboembolic risk 
after catheter ablation for atrial fibrillation. Heart Rhythm. 2014;11(12):2239-46  
68 Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M. Left atrial appendage 
dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc 
Electrophysiol. 2011;22(1):10-5 
69 Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology 
correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. 
J Am Coll Cardiol. 2012;60(6):531-8 
70 Wang Y, Di Biase L, Horton RP, Nguyen T, Morhanty P, Natale A. Left atrial appendage studied 
by computed tomography to help planning for appendage closure device placement. J Cardiovasc 
Electrophysiol. 2010;21(9):973-82. 
22  
                                                                                                                                                                                        
71 Anselmino M, Scaglione M, Di Biase L, et al. Left atrial appendage morphology and silent 
cerebral ischemia in patients with atrial fibrillation. Heart Rhythm. 2014;11(1):2-7. 
72 Kimura T, Takatsuki S, Inagawa K, et al. Anatomical characteristics of the left atrial appendage 
in cardiogenic stroke with low CHADS2 scores. Heart Rhythm. 2013;10(6):921-5. 
73 Kosiuk J, Nedios S, Kornej J, et al. Impact of left atrial appendage morphology on peri-
interventional thromboembolic risk during catheter ablation of atrial fibrillation. Heart Rhythm. 
2014;11(9):1522-7 
74 Khurram IM, Dewire J, Mager M, et al. Relationship between left atrial appendage morphology 
and stroke in patients with atrial fibrillation. Heart Rhythm. 2013;10(12):1843-9 
75 Petersen M, Roehrich A, Balzer J, et al. Left  atrial appendage morphology is closely associated 
with specific echocardiographicflow pattern in patients with atrial fibrillation. Europace. 2014. pii: 
euu347. 
76 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's 
triad revisited. Lancet. 2009;373(9658):155-66. 
77 Wong JM, Welles CC, Azarbal F, Whooley MA, Schiller NB, Turakhia MP. Relation of left 
atrial dysfunction to ischemic stroke in patients with coronary heart disease (from the heart and soul 
study). Am J Cardiol. 2014;113(10):1679-84 
78 Cameli M, Lisi M, Focardi M, et al. Left atrial deformation analysis by speckle tracking 
echocardiography for prediction of cardiovascular outcomes. Am J Cardiol. 2012;110(2):264-9 
79 Gupta DK, Shah AM, Giugliano RP, et al. Effective aNticoaGulation with factor xA next 
GEneration in AF-Thrombolysis In Myocardial Infarction 48 Echocardiographic Study 
Investigators. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur 
Heart J. 2014;35(22):1457-65 
80 Islas F, Olmos C, Vieira C, et al. Thromboembolic Risk in Atrial Fibrillation: Association 
between Left Atrium Mechanics and Risk Scores. A Study Based on 3D Wall-Motion Tracking 
23  
                                                                                                                                                                                        
Technology. Echocardiography. 2014. doi: 10.1111/echo.12711. 
81 Kuppahally SS, Akoum N, Burgon NS, et al. Left atrial strain and strain rate in patients with 
paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected 
by delayed-enhancement MRI. Circ Cardiovasc Imaging. 2010;3(3):231-9 
82 Li Y, Ding W, Wang H, et al. Relationship of CHA2DS2-VASc and CHADS2 Score to Left 
Atrial Remodeling Detected by Velocity Vector Imaging in Patients with Atrial Fibrillation. PLoS 
ONE 8(10): e77653. doi:10.1371/journal.pone.0077653  
83 Saha SK, Anderson PL, Caracciolo G, et al. Global Left Atrial Strain Correlates with CHADS2 
Risk Score in Patients with Atrial Fibrillation. J Am Soc Echocardiogr 2011;24:506-12  
84 Obokata M, Negishi K, Kurosawa K, et al. Left atrial strain provides incremental value for 
embolism risk stratification over CHA₂DS₂-VASc score and indicates prognostic impact in patients 
with atrial fibrillation. J Am Soc Echocardiogr. 2014;27(7):709-716 
85 Azemi T, Rabdiya VM, Ayirala SR, McCullough LD, Silverman DI. Left atrial strain is reduced 
in patients with atrial fibrillation, stroke or TIA, and low risk CHADS(2) scores. J Am Soc 
Echocardiogr. 2012;25(12):1327-32 
86 Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in 
nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke 
Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12(12):1080-7 
87 Takahashi N, Nakamura Y, Komatsu S, Kusano KF, Ohe T. The feasibility of tissue Doppler 
acceleration as a new predictor of thrombogenesis in the left atrial appendage associated with 
nonvalvular atrial fibrillation. Echocardiography. 2008;25(1):64-71 
88 Parvathaneni L, Mahenthiran J, Jacob S, et al. Comparison of tissue Doppler dynamics to 
Doppler flow in evaluating left atrial appendage function by transesophageal echocardiography. Am 
J Cardiol. 2005;95(8):1011-4 
24  
                                                                                                                                                                                        
89 Sallach JA, Puwanant S, Drinko JK, et al. Comprehensive left atrial appendage optimization of 
thrombus using surface echocardiography: the CLOTS multicenter pilot trial. J Am Soc 
Echocardiogr. 2009;22(10):1165-72 
90 Tamura H, Watanabe T, Hirono O, et al. Low wall velocity of left atrial appendage measured by 
trans-thoracic echocardiography predicts thrombus formation caused by atrial appendage 
dysfunction. J Am Soc Echocardiogr. 2010;23(5):545-552 
91  Yoshida N, Okamoto M, Hirao H, et al. Role of transthoracic left atrial appendage wall motion 
velocity in patients with persistent atrial fibrillation and a low CHADS2 score. J Cardiol 
2012;60(4):310-5 
92 Tamura H, Watanabe T, Nishiyama S, et al. Prognostic value of low left atrial appendage wall 
velocity in patients with ischemic stroke and atrial fibrillation. J Am Soc Echocardiogr. 
2012;25(5):576-83 
93 Masuda M, Iwakura K, Inoue K, et al. Estimation of left atrial blood stasis using diastolic late 
mitral annular velocity. Eur Heart J Cardiovasc Imaging. 2013;14(8):752-7 
94 Providência R, Faustino A, Ferreira MJ, et al. Evaluation of left atrial deformation to predict left 
atrial stasis in patients with non-valvular atrial fibrillation - a pilot-study. Cardiovasc Ultrasound. 
2013;11:44 
95 Muellerleile K, Sultan A, Groth M, et al. Velocity encoded cardiovascular magnetic resonance to 
assess left atrial appendage emptying. J Cardiovasc Magn Reson. 2012;14:39 
 
 
 
 
 
 
25  
                                                                                                                                                                                        
FIGURE LEGENDS 
Figure 1. Late-gadolinium enhanced (LGE) magnetic resonance images representing fibrotic areas 
of left atrium as seen in antero-posterior view. The four images show different stages of increasing 
LGE burden (Utah classes, divided by quartiles): stage I (A: 2.7% enhancement), Stage II (B: 
10.2% enhancement), Stage III (C: 19.4%), and Stage IV (D: 38.4% enhancement). Left atrial 
enhancement is represented as green areas to enhance contrast with non-enhanced tissue. Higher 
stages have been associated with LA appendage thrombi and history of previous stroke (see text for 
details). Reproduced with permission from Daccarett M et al. J Am Coll Cardiol 2011;57:831-8. 
 
Figure 2. Left atrial appendage morphologies as represented in order of increasing complexity, 
which has been reported to relate to a growing burden of silent cerebral ischemia: from the simpler, 
Cactus (A, a dominant central lobe with small chambers extending in all directions), to the more 
complex, Cauliflower (D, complex internal characteristics with lack of a dominant lobe). 
Intermediate forms Chicken Wing (B, an obvious bend in the proximal or middle part of the 
dominant lobe) and Wind Sock (C, a dominant lobe plus secondary or even tertiary lobes arising 
from the dominant lobe) are as well represented.  Reproduced with permission from Anselmino M 
et al. Heart Rhythm 2014;11(1):2-7. 
 
Figure 3. Left atrial appendage wall velocity (TTE-LAWV) as measured by trans-thoracic tissue 
Doppler imagin (DTI). Placing sample volume at left atrial appendage (LAA) tip from the 
parasternal short-axis view in diastole, DTI velocities were obtained and the peak wall velocity of 
downward atrial waveform within each RR interval was averaged. Reduced TTE-LAWV related to 
history of previous stroke and predicted recurrent cerebrovascular events at follow up in those same 
patients92. AoV, Aortic valve. Reproduced with permission from Tamura H et al. J Am Soc  
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Table 1. Left atrial and appendage parameters tested for thromboembolic risk prediction in AF 
patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
